点击图片查看原图
硫酸镁溶液
二苯胺
SDS-PAGE凝胶制备试剂盒
通过认证 
Aclidinium Bromide
FH1(BRD-K4477)
MK-801 (Dizocilpine)
Venetoclax (ABT-199,
TSU-68 (SU6668, Oran
Sapogenins Glycoside| 货号： | S3200 |
| 规格： | 5mg/10mM/1mL/10mg/25mg |
更多详情请访问中国唯一官方网站：http://www.selleck.cn/products/triflusal.html
生物活性
| 产品描述 | Triflusal是一种抗血栓药剂，通过乙酰化环氧化酶-1来不可逆的抑制血小板中血栓素-B2的产生。 | |||||
|---|---|---|---|---|---|---|
| 靶点 | ||||||
| IC50 | ||||||
| 体外研究 | The main Triflusal metabolite, HTB, preserves 6-keto-PGF1α synthesis in porcine aortic endothelial cells (PAEC) cells without a significant decline for up to 24 h even at the higher concentration. [1] Triflusal at 10 mM, 100 mM and 1 M decreases LDH efflux in rat brain slices after anoxia/reoxygenation by 24%, 35% and 49% respectively. Triflusal also reduces inducible NO synthase activity by 18%, 21% and 30%. [2] | |||||
| 体内研究 | Triflusal (10 mg/kg i.v.) reduces platelet deposition on subendothelium-induced primary thrombus by about 68% in rabbits. Triflusal (10 mg/kg i.v.) reduces platelet deposition on a fresh thrombus formed over tunica media by about 48% in rabbits. Triflusal (40 mg/kg p.o.) reduces platelet deposition on a primary thrombus triggered by subendothelium and tunica media by 53% in rabbits. Triflusal (40 mg/kg p.o.) significantly reduces Cox-2 mRNA levels and protein levels without influence Cox-1 mRNA levels on the vascular wall in rabbits. [1] Triflusal (600 mg/day for 5 days) results in an increase in NO production by neutrophils and an increase in endothelial nitric oxide synthase (eNOS) protein expression in neutrophils in healthy volunteers. [3] Triflusal (300 mg, twice-daily orally) shows a more important increase in total walking distance and in pain-free walking distance over the basal values than those treated with placebo, together with an improvement of the symptomatology correlated with claudication in patients with chronic peripheral arteriopathy. Triflusal (300 mg, twice-daily orally) shows an increase in the peak-flow recorded through strain-gauge plethysmography in patients with chronic peripheral arteriopathy. [4] Triflusal (30 mg/kg) strongly decreases iNOS immunolabeling at both survival times analyzed, attenuating iNOS immunoreactivity in astroglial cells and infiltrated neutrophils in rats. Triflusal (30 mg/kg) decreases neuronal and microglial COX-2 expression at 10 and 24 hours after lesion and microglial and astroglial expression of IL-1beta and TNF-alpha at 24 hours after lesion in rats. [5] | |||||
| 临床实验 | Triflusal is in phase 4 clinical trial in patients with Vasospastic Syndrome. | |||||
温馨提示：不可用于临床治疗。
